Invigor gains data intelligence government contract

|

Published 15-MAR-2018 12:03 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Invigor Group Limited (ASX:IVO) has secured a new contract valued at $100,000 for stage one of IPART’s data requirements for its review of the Container Deposit Scheme (CDS).

IPART is an independent pricing and regulatory tribunal, which oversees the regulation of the beverage, gas, electricity and transport industries in New South Wales.

The body will utilise IVO’s extensive data on alcoholic beverage pricing – which includes seven years of historical data – to assess the impact of the CDS on container beverage prices, the performance and conduct of suppliers and other factors which could impact consumers.

Because stage one of IPART’s analysis will be geared around historical data, the contract will generate instantaneous revenues for IVO, which is strongly positioned to clinch stages two and three of the contract moving forward.

The freshly inked contract is a significant development for the analytics solutions company, which has continued its strong track record of winning large revenue-generating data intelligence contracts.

With an exceptional pipeline of upcoming tenders mounting, IVO expects additional tender-to-contract conversions over the rest of 2018.

Of course, it should be noted that Invigor is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.

IVO CEO Gary Cohen commented on the new contract, “Our steady growth of locking in new and larger revenue-generating data intelligence and analytics contracts with blue chip customers, recognised brands and government departments is continuing in 2018,” he said.

“It’s a pleasing contract win, and we’re delighted to be working with the NSW Government as it gives us great exposure across this large sector and positions us as a dependable and credible public sector technology provider.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X